Heron agreed to sell most of its assets for cash and CorMedix shares, and plans to repay debt. The cash helps, but it gives up most operations and has not chosen its next business plan.
The cash and shares would give Heron resources, and paying off its working-capital debt would ease a cash burden. But it would give up most of its assets, and the board has not chosen what to do next. Those facts leave its outlook balanced.
CorMedix agreed to acquire Heron's assets and take on certain liabilities, in exchange for cash, shares, and possible future payments. The filing does not show whether the assets' value will exceed the cost.
Follow Heron Therapeutics, Inc. (HRTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HRTX